Skip to main content
. Author manuscript; available in PMC: 2021 Apr 15.
Published in final edited form as: J Am Chem Soc. 2020 Apr 1;142(15):6970–6982. doi: 10.1021/jacs.9b13159

Figure 7.

Figure 7.

Bioactivity of dimer-bleomycin conjugate 5 in MDA-MB-231 triple negative breast cancer cells. (A) Effect of cleaving compound 5 and negative control compound 6 on pri-miR-17–92 levels in MDA-MB-231 cells, as determined by RT-qPCR. (B) Competition experiment between dimer binder 2 and 5 and their effect of pri-miR-17–92 levels, as determined by RT-qPCR. (C) Effect of 5 on pre-miR-17 levels, as determined by RT-qPCR. (D) Effect of 5 on the levels of mature miRNAs derived from the miR-17–92 cluster, as determined by RT-qPCR. (E) Effect of 5 on Zbtb4 mRNA levels, a direct target of miR-17, as determined by RT-qPCR. (F) Effect of 5 on ZBTB4 expression in MDA-MB-231 cells. (G) Effect of 5 on the invasive characteristics of MDA-MB-231 cells, due to repression of ZBTB4. Errors are reported as SEM *, p < 0.05; **, p < 0.01; ***, p < 0.001, as determined by a Student t test.